Peer Exchange

Impact of HIV Guideline Changes on Payer Decisions
February 27, 2018 – 
Peter L. Salgo, MD; Michael Sension, MD; and Jeffrey Dunn, PharmD, discuss the need for more individualized therapy in HIV and the impact of guideline updates on payer decisions.
HIV Guideline Update
February 21, 2018 – 
Peter L. Salgo, MD; Michael Sension, MD; Jeffrey Dunn, PharmD; and Elly Fatehi, PharmD, MPH, review the updates to the HHS treatment guideline for most people with human immunodeficiency virus.
Goals of Therapy in HIV Infection
February 21, 2018 – 
Peter L. Salgo, MD; Elly Fatehi, PharmD, MPH; Michael Sension, MD; and Jeffrey Dunn, PharmD, provide an overview on the goals of therapy in HIV infection, including preventing transmission.
Today's HIV Treatment Challenges
January 24, 2018 – 
Peter L. Salgo, MD; Elly Fatehi, PharmD, MPH; Michael Sension, MD; and Jeffrey Dunn, PharmD, offer their perspectives on the current treatment challenges with HIV infection, including medication adherence.
HIV: Achieving Normal Life Expectancy
January 22, 2018 – 
Peter L. Salgo, MD; Michael Sension, MD; Elly Fatehi, PharmD, MPH; and Jeffrey Dunn, PharmD, provide a historic perspective regarding HIV treatment outcomes and the achievability of a normal life expectancy.
Special Considerations in HIV Management
December 27, 2017 – 
Throughout this AJMC Peer Exchange®, a panel of experts in infectious disease and managed care will discuss today’s management of HIV, including the need for individualized care and the role for newer treatment options.
Impact of Cardiovascular Evidence on Diabetes
October 02, 2017 – 
John B. Buse, MD, PhD, discusses the potential impact that the recent cardiovascular outcomes trials will have on clinical decision making and future research in diabetes.
Understanding Cardiovascular Benefit With the LEADER Trial
October 02, 2017 – 
John B. Buse, MD, PhD, offers his perspective on the LEADER trial with liraglutide and the potential reasons for the cardiovascular effects in patients with type 2 diabetes.
The Importance of Real-World Data in Type 2 Diabetes
September 27, 2017 – 
Mark Warren, MD, discusses the role for real-world studies in type 2 diabetes and outlines important factors to consider when evaluating the relevance of the findings.
Understanding the DUAL VII Findings in Type 2 Diabetes
September 27, 2017 – 
Mark Warren, MD, provides context to the efficacy and safety findings from the DUAL VII trial with liraglutide plus insulin degludec in patients with type 2 diabetes.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!